Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy Simon Baldacci, Elliott J. Brea, Francesco Facchinetti, Zhaorong Li, Kenneth Ngo, Soumya Malhotra, Matthew A. Booker, Michael Yevgeniy Tolstorukov, Sachiv Chakravarti, Conor Hinchey, Navin R. Mahadevan, Filippo Lococo, Simona D’Agnelli, Letizia Gnetti, Nicoletta Campanini, Alessandro Leonetti, William W. Feng, Jeanelle A. Tsai, Antja-Voy Hartley, Marie-Anaïs Locquet, Ludovic Fournel, Marco Alifano, Audrey Mansuet-Lupo, Aisha Saldanha, William Haller, Lauren M. Zasadil, Magdalena Zielinska, Karen Bui, Bishma Tuladhar, Patrick Hall Lizotte, Elena V. Ivanova, Lecia V. Sequist, Prafulla C. Gokhale, Cloud P. Paweletz, Eric L. Smith, Pasi A. Jänne, David A. Barbie Cancer Discovery, 2025 EGFR tyrosine kinase inhibitors have dramatically improved outcomes for patients with EGFR-mutated non–small cell lung cancer (NSCLC), but relapse frequently occurs because of drug-tolerant persister (DTP) cells that can evolve and develop diverse mechanisms of drug resistance. In samples from patients with EGFR-mutated NSCLC treated with EGFR tyrosine kinase inhibitors in the neoadjuvant setting, we observed enriched expression of the cell surface protein TROP2, a target of clinically active antibody–drug conjugates (ADC). We confirmed these findings across multiple EGFR-mutated NSCLC cell line and patient-derived xenograft models treated with osimertinib in vivo. Treatment with the TROP2 ADC sacituzumab govitecan at the time of osimertinib-induced minimal residual disease only modestly delayed tumor recurrence in vivo, whereas a single infusion of sacituzumab-based TROP2-directed chimeric antigen receptor (CAR) T cells significantly prolonged relapse-free survival, with evidence of cure. These data highlight the potential of engineering TROP2 CAR T-cell therapy to eliminate EGFR DTPs in patients. Significance: We provide a rationale for targeting TROP2 in EGFR-mutated NSCLC DTPs. In contrast to TROP2 ADC therapy, targeting of TROP2 with CAR-T cells can eliminate osimertinib-induced DTPs in vivo, revealing the promise of developing novel TROP2-based CAR-T cells to promote durable response and prevent disease relapse in patients.
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature Marianna Peroni, Alessandro Leonetti, Roberta Minari, Michela Verzè, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni, Marco Galaverni, Nicola Simoni, Gabriele Missale, Elisabetta Biasini, Marcello Tiseo Jto Clinical and Research Reports, 2025 fusions as an acquired resistance mechanism to osimertinib and potential treatment strategies.
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab Giulia Claire Giudice, Sara Elena Rebuzzi, Giulia Mazzaschi, Federica Pecci, Michele Maffezzoli, Alessandro Acunzo, Letizia Gnetti, Enrico Maria Silini, Giuseppe Caruso, Elena Rapacchi, Pasquale Rescigno, Giuseppe Fornarini, Giuseppe Luigi Banna, Sebastiano Buti Cancer Treatment and Research Communications, 2025 • Prognostic and predictive factors are essential for choosing the best treatment option for renal cell carcinoma (RCC). • A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is a positive prognostic factor. • We analyzed the prognostic value of Hb/RDW ratio in a cohort of RCC receiving nivolumab in later lines. • The Hb/RDW ratio did not show prognostic value in this setting. Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab. This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS). 356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS ( p < 0.001) and PFS ( p = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS. The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report Ilaria Gandolfini, Martina Manini, Giuseppe Daniele Benigno, Micaela Gentile, Alessandra Palmisano, Danio Somenzi, Letizia Gnetti, Marco Delsante, Benedetta Mordà, Marta D’Angelo, Daniel Salvetti, Enrico Fiaccadori, Sebastiano Buti, Umberto Maggiore Frontiers in Oncology, 2025 We report on the first case of a dual-kidney transplant recipient diagnosed with a metastatic BK polyomavirus-positive clear renal cell carcinoma with sarcomatoid features, which caused extensive vena cava thrombosis. The patient was successfully treated with the immune checkpoint inhibitors (ICIs) ipilimumab plus nivolumab and continued immunosuppression with tacrolimus, mycophenolate, and steroids. He received ICIs despite the presence of graft dysfunction due to transplant glomerulopathy. As expected, the ICI treatment caused a progressive but asymptomatic decline of the graft function, which resulted in end-stage kidney disease. However, continuation of a full immunosuppression prevented acute rejection, graft intolerance syndrome episodes, or dual graft nephrectomy, which enabled the patient to successfully continue ICIs while on dialysis and to achieve sustained partial remission at the 17-month follow-up.
Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients Matteo Canale, Alessandra Virga, Davide Angeli, Eugenio Fonzi, Letizia Gnetti, Alessandra Dubini, Gianluca Tedaldi, Milena Urbini, Giovanni Bocchialini, Elisabetta Petracci, Alberto Verlicchi, Paola Cravero, Fabrizio Citarella, Chiara Bennati, Kalliopi Andrikou, Angelo Delmonte, Lucio Crinò, Paolo Carbognani, Paola Ulivi, Luca Ampollini Lung Cancer Targets and Therapy, 2025 Purpose Lung Squamous Cell Carcinoma (SCC) is a Non-Small Cell Lung Cancer (NSCLC) subtype with a strong clinical association with smoking habits and a very low incidence in never-smokers. Molecular profiling of SCC in never-smokers could unveil tumor vulnerabilities and new treatment strategies. Patients and Methods We considered a patient cohort of 17 former or current smokers (51.5%) and 16 never-smoker SCC patients (48.5%). TruSight Oncology® 500, investigating hotspots in 523 cancer-related genes, Tumor mutation burden (TMB) and microsatellite instability (MSI), and RNA sequencing was performed on tumor tissue. Genomic and transcriptomic profiles were compared between smokers and never-smoker patients. Results The most frequently altered genes were TP53 (67%), CDKN2A (20%) and PIK3CA (17%), with no substantial differences between groups, except for TP53 which was more frequently mutated in smokers (86.7% vs 46.7%, p = 0.05), who also showed a higher TMB with respect to non-smokers (median 11 mut/Mb vs 5.5 mut/Mb, p = 0.028); all patients were stable for MSI score (median 1.87 vs 1.82, p = 0.87). Activating mutations in EGFR and MET were found in one and two never-smokers, respectively. Three smoker patients had simultaneous amplifications in FGF3, FGF19 and FGF4. Enrichment analyses showed that cyclin-dependent protein Ser/Thr kinase activity and PI3K signaling pathways were affected in both groups, while cellular damage response was exclusively altered in never-smokers. Unsupervised hierarchical clustering on transcriptomes effectively identified different specific transcriptional subtypes between smokers and never-smokers. Gene set enrichment analysis highlighted that tumors from never-smokers are characterized by dysregulation in cell membrane potential and ion homeostasis across cell membrane pathways. Conclusion Genomic and transcriptomic profiles deeply differentiate SCC occurring in never-smokers with respect to SCC in smoker patients. Moreover, SCC could carry canonical NSCLC) activating mutations. Our data suggest that deep molecular analyses resolve tumor heterogeneity and may help with new algorithm-based treatment strategies for SCC.
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy Giulia Mazzaschi, Roberto Rosati, Simona D’Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni, Gianmarco Martines, Monica Pluchino, Ilaria Toscani, Alessandro Leonetti, Fabiana Perrone, Paola Bordi, Giovanni Bocchialini, Luca Ampollini, Federico Quaini, Marcello Tiseo Immunotherapy, 2025 Aim A translational multiscale approach, encompassing tumor immune microenvironment (TIME), circulating immune-inflammatory benchmarks, and transcriptomic profiles, was undertaken to identify prognostic biomarkers of immunotherapy (IT) efficacy in patients with advanced pleural mesothelioma (PM).Methods Advanced PM patients (n = 17) treated with nivolumab plus ipilimumab were prospectively enrolled in the FIL-QI 2021 study. Baseline blood and tumor samples were analyzed for immune subsets and functional markers (Granzyme B, Ki67) by flow cytometry, cytokines by multiplex ELISA, TILs and PD-L1 by immunohistochemistry, and gene expression by nanostring. Associations with overall survival (OS), progression-free survival (PFS), time-to-treatment failure (TTF), and modified disease control rate (mDCR) were assessed.Results Higher baseline CD4+ GnzB+ T cells were significantly associated with OS ≥ 12 months (p < 0.001), PFS ≥ 6 months (p = 0.027), and TTF ≥ 6 months (p = 0.016), along with lower CD14+ monocytes (PFS: p = 0.038). Elevated proliferating CD8+ Ki67+ T cells (PFS: p = 0.038; TTF: p = 0.022) also predicted improved outcomes. Low IL-2 levels correlated with OS ≥ 12 months (p = 0.02). TIME analysis showed higher intratumor CD4+ TILs (p = 0.03) and CD4/CD8 ratio (p = 0.016) in long survivors. Transcriptomics revealed nine genes differentially regulated according to clinical outcomes, among which ULBP2 emerged as a strong predictor of poor prognosis (LASSO-Cox regression model).Conclusion Parallel immune and transcriptomic profiling identifies biomarkers predictive of IT benefit in PM.
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making Fabiana Perrone, Francesco Facchinetti, Benedetta Pellegrino, Roberta Minari, Letizia Gnetti, Cinzia Azzoni, Lorena Bottarelli, Nicoletta Campanini, Juan Francisco Grau-Bejar, Anna Mingozzi, Valeria Cognigni, Marcello Tiseo Tumori, 2024 Introduction: Several biomarkers are currently available to address targeted treatments in cancer patients, with lung malignancies representing one of the best examples. Case description: We report the case of a patient affected by advanced non-small cell lung cancer with an uncommon histology and a complex biology. The use of a large next-generation sequencing (NGS) NGS panel allowed us to identify an extremely rare BRAF mutation (V600Q), a MET amplification, a high tumor mutational burden, a germline pathogenetic BRCA1 mutation and a homologous recombination deficiency through RAD51 assay. The treatment decision was driven by the abundance of molecular information. Conclusions: This case highlights that an attentive and critical evaluation of molecular reports is key for the tailoring of treatment algorithms at the patient-level scale.
CD26 Is Differentially Expressed throughout the Life Cycle of Infantile Hemangiomas and Characterizes the Proliferative Phase Bruno Lorusso, Antonella Nogara, Rodanthi Fioretzaki, Emilia Corradini, Roberta Bove, Giovanni Roti, Andrea Gherli, Anna Montanaro, Gregorio Monica, Filippo Cavazzini, Sabrina Bonomini, Gallia Graiani, Enrico Maria Silini, Letizia Gnetti, Francesco Paolo Pilato, Giuseppe Cerasoli, Federico Quaini, Costanza Anna Maria Lagrasta International Journal of Molecular Sciences, 2024
Onset of ANCA-positive EGPA with bilateral pleural effusion: a case report Alessandra Marchese, Rocco Accogli, Annalisa Frizzelli, Alessandro De Simoni, Olha Bondarenko, Roberta Pisi, Gaetano Caramori, Giovanna Pelà, Maria Majori, Letizia Gnetti, Agnese Aluia, Lorenzo D’Aloisio, Alfredo Chetta, Marina Aiello Current Medical Research and Opinion, 2024
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey Nicola Fusco, Mariia Ivanova, Chiara Frascarelli, Carmen Criscitiello, Bruna Cerbelli, Maria Gemma Pignataro, Angelina Pernazza, Elham Sajjadi, Konstantinos Venetis, Giulia Cursano, Fabio Pagni, Camillo Di Bella, Marina Accardo, Michelina Amato, Paolo Amico, Caterina Bartoli, Giuseppe Bogina, Laura Bortesi, Renzo Boldorini, Sara Bruno, Daniela Cabibi, Pietro Caruana, Emanuele Dainese, Elisa De Camilli, Vladimiro Dell’Anna, Loren Duda, Carmela Emmanuele, Giuseppe Nicolò Fanelli, Bethania Fernandes, Gerardo Ferrara, Letizia Gnetti, Alessandra Gurrera, Giorgia Leone, Raffaella Lucci, Cristina Mancini, Grazia Marangi, Mauro G. Mastropasqua, Lorenzo Nibid, Sandra Orrù, Maria Pastena, Monica Peresi, Letizia Perracchio, Angela Santoro, Vania Vezzosi, Claudia Zambelli, Valeria Zuccalà, Antonio Rizzo, Leopoldo Costarelli, Francesca Pietribiasi, Alfredo Santinelli, Cristian Scatena, Giuseppe Curigliano, Elena Guerini-Rocco, Maurizio Martini, Paolo Graziano, Isabella Castellano, Giulia d'Amati Critical Reviews in Oncology Hematology, 2023
European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database Isabelle Opitz, Andrea Bille, Urania Dafni, Kristiaan Nackaerts, Luca Ampollini, Marc de Perrot, Luka Brcic, Ernest Nadal, Konstantinos Syrigos, Steven G. Gray, Joachim Aerts, Alessandra Curioni-Fontecedro, Jan H. Rüschoff, Kim Monkhorst, Birgit Weynand, Enrico Maria Silini, Fatemeh Bavaghar-Zaeimi, Marko Jakopovic, Roger Llatjos, Sotirios Tsimpoukis, Stephen P. Finn, Jan von der Thüsen, Nesa Marti, Georgia Dimopoulou, Roswitha Kammler, Solange Peters, Rolf A. Stahel, Pierre-Emmanuel Falcoz, Alessandro Brunelli, Paul Baas, Rolf Stahel, Anita Hiltbrunner, Rosita Kammler, Nesa Marti, Barbara Ruepp, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Androniki Stavrou, Jan H. Rüschoff, Martina Haberecker, Susanne Dettwiler, Fabiola Prutek, Christiane Mittmann, Isabelle Opitz, Bart Vrugt, Martina Friess, Alessandra Matter, Chloé Spichiger-Häusermann, Michaela B. Kirschner, Emanuela Felley-Bosco, Paul Baas, Kim Monkhorst, Kristiaan Nackaerts, Eric Verbeken, Birgit Weynand, Philippe Nafteux, Johnny Moons, Liesbet Peeters, Luca Ampollini, Marcello Tiseo, Enrico Maria Silini, Letizia Gnetti, Paolo Carbognani, Marc de Perrot, Fatemeh Bavaghar-Zaeimi, Luka Brcic, Miroslav Samarzija, Sven Seiwerth, Marko Jakopovic, Ernest Nadal, Felipe Cardenal, Roger Llatjos, Susana Lorente, Konstantinos Syrigos, Ioannis Vamvakaris, Sotirios Tsimpoukis, Paraskevi Boura, Steven G. Gray, Stephen P. Finn, Mutaz Mohammed Nur, Anne-Marie Baird, Martin P. Barr, Sinead Cuffe, Kathy Gately, Joachim Aerts, Jan von der Thüsen, Andrea Bille, Stefano Passani, Alessandro Brunelli Journal of Thoracic Oncology, 2023
Therapeutic Outcomes and Clinical Features of Advanced Non–Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study Giulia Mazzaschi, Fabiana Perrone, Roberta Minari, Michela Verzè, Cinzia Azzoni, Lorena Bottarelli, Monica Pluchino, Maria Pia Armillotta, Annalisa Ubaldi, Annalisa Altimari, Elisa Gruppioni, Francesca Sperandi, Elisa Andrini, Giorgia Guaitoli, Stefania Bettelli, Lucia Longo, Federica Bertolini, Fausto Barbieri, Maria Pagano, Candida Bonelli, Elena Tagliavini, Davide Nicoli, Alessandro Ubiali, Adriano Zangrandi, Serena Trubini, Manuela Proietto, Letizia Gnetti, Marcello Tiseo Clinical Lung Cancer, 2022
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro Bruno Lorusso, Giuseppe Cerasoli, Angela Falco, Caterina Frati, Gallia Graiani, Denise Madeddu, Antonella Nogara, Emilia Corradini, Giovanni Roti, Elisa Cerretani, Andrea Gherli, Mariafrancesca Caputi, Letizia Gnetti, Francesco Paolo Pilato, Federico Quaini, Costanza Lagrasta Vascular Pharmacology, 2022
Prognostic role of standard uptake value according to pathologic features of lung adenocarcinoma Pietro Bertoglio, Luigi Ventura, Vittorio Aprile, Maria Angela Cattoni, Dania Nachira, Filippo Lococo, Maria Rodriguez Perez, Francesco Guerrera, Fabrizio Minervini, Letizia Gnetti, Diana Bacchin, Francesca Franzi, Giulia Querzoli, Guido Rindi, Salvatore Bellafiore, Federico Femia, Andrea Viti, Peter Kestenholz, Enrico Ruffini, Massimiliano Paci, Stefano Margaritora, Andrea Selenito Imperatori, Marco Lucchi, Paolo Carbognani, Alberto Claudio Terzi Tumori, 2022
Impact of High-Grade Patterns in Early-Stage Lung Adenocarcinoma: A Multicentric Analysis Pietro Bertoglio, Vittorio Aprile, Luigi Ventura, Maria Cattoni, Dania Nachira, Filippo Lococo, Maria Rodriguez Perez, Francesco Guerrera, Fabrizio Minervini, Giulia Querzoli, Giovanni Bocchialini, Diana Bacchin, Francesca Franzi, Guido Rindi, Salvatore Bellafiore, Federico Femia, Giuseppe Salvatore Bogina, Piergiorgio Solli, Peter Kestenholz, Enrico Ruffini, Massimiliano Paci, Stefano Margaritora, Andrea Selenito Imperatori, Marco Lucchi, Letizia Gnetti, Alberto Claudio Terzi Lung, 2022
Pathological and clinical features of multiple cancers and lung adenocarcinoma: a multicentre study Pietro Bertoglio, Luigi Ventura, Vittorio Aprile, Maria Angela Cattoni, Dania Nachira, Filippo Lococo, Maria Rodriguez Perez, Francesco Guerrera, Fabrizio Minervini, Letizia Gnetti, Alessandra Lenzini, Francesca Franzi, Giulia Querzoli, Guido Rindi, Salvatore Bellafiore, Federico Femia, Giuseppe Salvatore Bogina, Diana Bacchin, Peter Kestenholz, Enrico Ruffini, Massimiliano Paci, Stefano Margaritora, Andrea Selenito Imperatori, Marco Lucchi, Luca Ampollini, Alberto Claudio Terzi Interactive Cardiovascular and Thoracic Surgery, 2022
Prognostic impact of lung adenocarcinoma second predominant pattern from a large European database Pietro Bertoglio, Giulia Querzoli, Luigi Ventura, Vittorio Aprile, Maria A. Cattoni, Dania Nachira, Filippo Lococo, Maria Rodriguez Perez, Francesco Guerrera, Fabrizio Minervini, Letizia Gnetti, Diana Bacchin, Francesca Franzi, Guido Rindi, Salvatore Bellafiore, Federico Femia, Andrea Viti, Giuseppe S. Bogina, Peter Kestenholz, Enrico Ruffini, Massimiliano Paci, Stefano Margaritora, Andrea S. Imperatori, Marco Lucchi, Luca Ampollini, Alberto C. Terzi Journal of Surgical Oncology, 2021
Cryptogenic fibrosing pleuritis Alessandra Anna Manco, Veronica Alfieri, Letizia Gnetti, Marina Aiello, Giuseppina Bertorelli, Maria Majori, Alfredo Chetta European Journal of Case Reports in Internal Medicine, 2021
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo Abdullah Alajati, Mariantonietta D’Ambrosio, Martina Troiani, Simone Mosole, Laura Pellegrini, Jingjing Chen, Ajinkya Revandkar, Marco Bolis, Jean-Philippe Theurillat, Ilaria Guccini, Marco Losa, Arianna Calcinotto, Gaston De Bernardis, Emiliano Pasquini, Rocco D’Antuono, Adam Sharp, Ines Figueiredo, Daniel Nava Rodrigues, Jonathan Welti, Veronica Gil, Wei Yuan, Tatjana Vlajnic, Lukas Bubendorf, Giovanna Chiorino, Letizia Gnetti, Verónica Torrano, Arkaitz Carracedo, Laura Camplese, Susumu Hirabayashi, Elena Canato, Gianfranco Pasut, Monica Montopoli, Jan Hendrik Rüschoff, Peter Wild, Holger Moch, Johann De Bono, Andrea Alimonti Journal of Clinical Investigation, 2020
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer Cecilia Bozzetti, Anna Squadrilli, Rita Nizzoli, Costanza Lagrasta, Donatello Gasparro, Maria Majori, Massimo De Filippo, Gabriella Becchi, Cinzia Azzoni, Nicoletta Campanini, Giuseppe Pedrazzi, Andrea Zavani, Enrico Maria Silini, Marcello Tiseo, Letizia Gnetti Immunotherapy, 2020
Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer Diletta Di Mitri, Michela Mirenda, Jelena Vasilevska, Arianna Calcinotto, Nicolas Delaleu, Ajinkya Revandkar, Veronica Gil, Gunther Boysen, Marco Losa, Simone Mosole, Emiliano Pasquini, Rocco D’Antuono, Michela Masetti, Elena Zagato, Giovanna Chiorino, Paola Ostano, Andrea Rinaldi, Letizia Gnetti, Mariona Graupera, Ana Raquel Martins Figueiredo Fonseca, Ricardo Pereira Mestre, David Waugh, Simon Barry, Johann De Bono, Andrea Alimonti Cell Reports, 2019
Lung Manifestations of IgG4-related Disease. A multifaceted disorder. Presentation of two cases and short review of the literature Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018
Pulmonary metastases from low grade sarcoma in a patient with pulmonary sarcoidosis. Sarcoidosis or sarcoid-like reaction? Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2016
Immagini in Pneumologia Interventistica Rassegna Di Patologia Dell Apparato Respiratorio, 2016
A case of solitary fibrous pleura tumor associated with severe hypoglycemia: The Doege-Potter’s syndrome Acta Biomedica, 2016
Spontaneous rupture of spleen: histological, immunohistochemical and ultrastructural study. Advances in Clinical Pathology the Official Journal of Adriatic Society of Pathology, 2003
Intranodal myofibroblastoma: a case report and review of literature. Advances in Clinical Pathology the Official Journal of Adriatic Society of Pathology, 2001
